Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Zolgensma
Zolgensma
With FDA decision near, Novartis bolsters SMA gene therapy case
Biopharma Dive
Wed, 04/17/19 - 09:57 am
Novartis
FDA
Zolgensma
spinal muscular atrophy
Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER
Fierce Pharma
Thu, 04/4/19 - 11:54 am
Novartis
ICER
drug pricing
Zolgensma
gene therapy
spinal muscular atrophy
2 Blockbuster Gene Therapy Programs to Watch in 2019
Motley Fool
Sun, 03/31/19 - 03:42 pm
gene therapy
Zolgensma
Novartis
Bluebird Bio
LentiGlobin
ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy
BioCentury
Sat, 02/23/19 - 04:36 pm
Novartis
Zolgensma
AVXS-101
spinal muscular atrophy
ICER
Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies
Fierce Pharma
Tue, 01/29/19 - 07:21 pm
Novartis
ICER
spinal muscular atrophy
alternative payments
drug pricing
gene therapy
Zolgensma
Novartis’ SMA Gene Therapy Is on the Fast Track for Approval
BioSpace
Mon, 12/3/18 - 05:55 pm
Novartis
gene therapy
SMA
AVXS-101
Zolgensma
priority review
FDA
Pages
« first
‹ previous
1
2
3
4
5